期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

瑞格列奈在2型糖尿病治疗中的应用 被引量：2

Application of repaglinide in patients with type 2 diabetes
下载PDF
导出
摘要 瑞格列奈为一种氨甲酰基苯甲酸类衍生物,其作用机制与磺酰脲类药物相似,均作用于β细胞上磺酰脲类药物受体,引起K+(KATP)通道关闭和Ca2+通道开放,最终促进胰岛素的分泌,所不同的是与SUR的结合位点不同,能改善胰岛素第1相分泌,在模拟餐时正常胰岛素分泌模式、降低餐后血糖水平方面有着杰出的表现。本文对瑞格列奈从药理学作用机制、药代动力学特点、在2型糖尿病中的应用、安全性与耐受性、适应证和禁忌证等方面进行综述。
作者 王煜
机构地区 成都市第六人民医院内分泌科
出处 《药品评价》 CAS 2014年第5期43-48,共6页 Drug Evaluation
关键词 糖尿病 瑞格列奈 磺酰脲类药物 药代动力学 安全性 耐受性 适应证 禁忌证
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献32

  • 1Christophe M, Anne LP, Renand D. SUR, ABC proteins targeted by KATP channel openers[J]. Journal of Molecular and Cellular Cardiology, 2005, (38): 951-957.
  • 2Owens DR. Repaglinide prandial glucose regulator: a new class of oral antidiabetic drugs[J]. Diabet Med, 1999, 15(4): 28-36.
  • 3刘旭霞,钮伟真.ATP敏感钾通道调控机制研究进展[J].医学研究通讯,2005,34(4):58-60. 被引量：3
  • 4Hatorp V, Huang WC, Strange P. Repaglinide pharmacokinetics in healthy young adult and elderly subjects[J]. Clin Ther, 1999, 21 : 702-710.
  • 5Derosa G, Salvadeo SA, D Angelo A, et al. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonyhtreas and metformin: a double-blind, cross-over, clinical Irial[J]. Curt Med Res Opin, 2009, 25(3): 607-615.
  • 6Jacobson-Dickman E, Levitsky L. Oral agents in managing diabetes mellitus in children and adolescents[J]. Pediatr Clin North Am, 2005, 52(6): 1689-1703.
  • 7Gribble FM, Reimann F. Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions[J]. J Diabetes Complications, 2003, 17 (Suppl 2): 11-15.
  • 8Ambavane V, Patil R, Ainapure SS. Repaglinide: a short acting insulin ecretagogue for postprandial hyperglycaemia[J]. J Postgrad Med, 2002, 48(3): 246-248.
  • 9Niemi M, Backman JT, Neuvonen M, et al. Eflects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and phannacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide[J]. Diabetoligia, 2003, 46(3): 347-351.
  • 10Tankova T, Koev D, Dakovska L, et al. The effect of repaglinide on insulin secretion and oxidative slress in type 2 diabetic patients[J]. Diabetes Res Clin Pmct, 2003, 59: 43-49.

二级参考文献40

  • 1潘长玉,中国区合作调查组.中国糖尿病控制现状——指南与实践的差距 亚洲糖尿病治疗现状调查1998,2001及2003年中国区结果介绍[J].国外医学（内分泌学分册）,2005,25(3):174-178. 被引量：396
  • 2Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes ( UKPDS 35 ) : prospective observational study. BMJ, 2000 ; 321:405- 412.
  • 3Culy CR, Jarvis B. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs, 2001,61:1625-1660.
  • 4Bailey C,J, Turner RC. Mefformin. N Engl J Med, 1996,334:574- 579.
  • 5Rudovich NN, Leyck-Dieken MG, Rochlitz H, et al. Enhancement of early- and late-phase insulin secretion and insulin sensitivity by the combination of repaglinide and mefformin in type 2 diabetes mellitns. Exp Clin Endocrinol Diabetes, 2004 , 112:395-400.
  • 6Moses R. Repaglinide in combination therapy with metformin in type 2 diabetes. Exp Clin Endocrinol Diabetes, 1999,107 ( Suppl 4 ) : S136- S139.
  • 7Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2006,29:1963-1972.
  • 8IDF Clinical Guidelines Task Force. Global Guideline for type 2 Diabetes. Brussels. International Diabetes Federation. 2005
  • 9Raskin P, Klaff L, McGill S, et al. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care, 2003,26:2063-2068.
  • 10The DCCT Research Group. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med, 1991,90:450- 459.

共引文献40

同被引文献20

引证文献2

二级引证文献11

药品评价
2014年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部